S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.58 HKD 3.77% Market Closed
Market Cap: 10.6B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SSY Group Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Cash from Investing Activities
-HK$662.8m
CAGR 3-Years
-31%
CAGR 5-Years
10%
CAGR 10-Years
4%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Cash from Investing Activities
-HK$515.7m
CAGR 3-Years
27%
CAGR 5-Years
34%
CAGR 10-Years
4%
U
United Laboratories International Holdings Ltd
HKEX:3933
Cash from Investing Activities
-ÂĄ1.7B
CAGR 3-Years
-61%
CAGR 5-Years
-23%
CAGR 10-Years
-7%
Sino Biopharmaceutical Ltd
HKEX:1177
Cash from Investing Activities
-ÂĄ757m
CAGR 3-Years
58%
CAGR 5-Years
26%
CAGR 10-Years
5%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Cash from Investing Activities
-HK$5.8B
CAGR 3-Years
-48%
CAGR 5-Years
2%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Cash from Investing Activities
$19.4m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
N/A
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
10.6B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
5.43 HKD
Undervaluation 34%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Cash from Investing Activities?
Cash from Investing Activities
-662.8m HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Cash from Investing Activities amounts to -662.8m HKD.

What is SSY Group Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
4%

Over the last year, the Cash from Investing Activities growth was -57%. The average annual Cash from Investing Activities growth rates for SSY Group Ltd have been -31% over the past three years , 10% over the past five years , and 4% over the past ten years .

Back to Top